首页|急性髓系白血病一线诱导方案相关进展

急性髓系白血病一线诱导方案相关进展

扫码查看
急性髓系白血病(acute myeloid leukemia,AML)是成人急性白血病中最常见的类型.蒽环类药物和阿糖胞苷组成的"3+7"方案自20世纪70年代被确立为AML患者的标准诱导方案.此后,不断有临床研究对一线诱导方案进行改良优化,并研究新方案和标准诱导方案相比,在疗效及安全性方面是否更具优势.文章主要阐述AML一线诱导治疗方案的相关进展及相关分子靶向药物的研究,为临床治疗提供参考.
Advances in first-line induction regimens for acute myeloid leukemia
Acute myeloid leukemia(AML)is the most common type of acute leukemia in adults.The"3+7"regimen composed of anthracyclines and cytarabine has been established as the standard induction regimen for AML patients since the 1970 s.Since then,on going clinical studies have focused on optimizing the first-line induction regimen and evaluating whether new regimens have more advantages in terms of efficacy and safety compared to the standard induction regimen.This article mainly describes the progress of first-line induction therapy regimens for AML,and the research of related molecular targeted drugs,so as to provide reference for clinical treatment.

acute myeloid leukemiainduction regimensadvancestargeted drugs

马萍、洪鸣

展开 >

南京医科大学第一附属医院血液科,江苏 南京 210029

急性髓系白血病 诱导治疗 进展 靶向药物

2025

南京医科大学学报(自然科学版)
南京医科大学

南京医科大学学报(自然科学版)

北大核心
影响因子:0.646
ISSN:1007-4368
年,卷(期):2025.45(1)